BioSpace News Archive

Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology

Puma Biotechnology announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma’s drug neratinib in patients with early stage HER2-positive breast cancer in the journal The Lancet Oncology.

November 13, 2017

·

10 min read

Business

DelMar Pharma Announces First Quarter Fiscal Year 2018 Financial Results

DelMar exec management will host a business update conference call and live webcast for investors, analysts and other interested parties on Tuesday, November 14, 2017 at 4:30 p.m. Eastern Standard Time.

November 13, 2017

·

22 min read

Genetown

Alnylam Pharmaceuticals Prices Public Offering of 5,600,000 Shares of Common Stock

Alnylam announced the pricing of an underwritten registered public offering of 5,600,000 shares of its common stock at a public offering price of $125.00 per share.

November 13, 2017

·

5 min read

Drug Development

Boehringer Ingelheim’s New RE-VERSE AD Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind) in Pradaxa Patients With GI Bleeding or Needing Emergency Surgery

The analyses provide further insights on the use of idarucizumab in patients with GI bleeding and in those with a need for urgent surgery or intervention.

November 13, 2017

·

13 min read

Drug Development

Kadmon Initiates Phase II Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease

The primary endpoint is the change from baseline in height-adjusted total kidney volume at 12 months.

November 13, 2017

·

4 min read

AmerisourceBergen Urges Policymakers to Support Regulator and Industry Data Transparency to More Effectively Combat Opioid Abuse

The Company is committed to working collaboratively to help mitigate controlled substance abuse, a complex national crisis, and has urged Congress to take action to enable stronger oversight of opioid ordering and distribution practices.

November 13, 2017

·

4 min read

Pharm Country

Synergy Pharmaceuticals Announces Pricing of Offering of Common Stock and Warrants

Synergy Pharmaceuticals announced the pricing of its underwritten offering of 21,705,426 shares of its common stock together with accompanying warrants to purchase an aggregate of 21,705,426 shares of common stock at a combined price to the public of $2.58 per share and accompanying warrant.

November 13, 2017

·

5 min read

Business

Repros Therapeutics Reports Third Quarter 2017 Financial Results

Net loss for the three month period ended September 30, 2017, was ($1.6) million or ($0.04) per share as compared to a net loss of ($4.2) million or ($0.17) per share for the same period in 2016.

November 13, 2017

·

7 min read

Business

ProPhase Labs Reports Financial Results for the Three Months and Nine Months Ended September 30, 2017

Net sales from continuing operations were $5.7 million for the nine months ended September 30, 2017, as compared to net sales of $3.4 million for the nine months ended September 30, 2016.

November 13, 2017

·

10 min read

Pharm Country

New Cancer Treatment Developed by LIMR Scientists Inhibits Tumor Growth and Boosts Anti-Tumor Immune Response

Cancer researchers at the Lankenau Institute for Medical Research have developed a novel treatment that inhibits the growth of malignant tumors and activates an immune response to those tumors.

November 13, 2017

·

3 min read